SOLID TUMORS

This early-stage study tests a new drug, GS-9911, alone or with an existing immunotherapy, in 45 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check safety and find the best dose. This is a first step to see if the drug might h…

This study tests a new experimental drug, BI 770371, given alone or with another drug called ezabenlimab, in adults with advanced solid tumors that have not responded to prior treatments. The main goal is to find a safe dose and check for side effects. Up to 36 participants will …

This study gives continued access to the cancer drug pertuzumab for people with solid tumors who were already benefiting from it in an earlier Roche-sponsored trial. About 154 participants will receive the drug until their disease worsens or side effects become unacceptable. The …

This early-phase study tests a combination of two drugs, palbociclib and gedatolisib, in people with advanced lung, pancreatic, head & neck, or other solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and to check for side effe…

This study tests a new drug called BI-1910, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 35 adu…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This early-phase study tests an experimental drug called M9140 in 12 Chinese patients with advanced colorectal cancer that has not responded to standard treatments. The drug works like a guided missile, delivering chemotherapy directly to cancer cells that carry a specific marker…

This early-stage study tests an experimental drug called JSI-1187, alone or with another drug (dabrafenib), in people with advanced solid tumors that have certain gene changes (MAPK pathway mutations). The main goal is to check safety and side effects. About 71 adults with tumors…

This study tests whether combining two drugs, olaparib and pembrolizumab, can shrink or control advanced solid tumors that have certain DNA repair problems. About 300 adults whose cancer has not responded to standard treatments will receive the drug combination. The goal is to se…

This study was designed to test a new cell therapy called B7H3 CAR-T for people with advanced solid tumors that have a specific marker (B7H3). The goal was to see if the treatment is safe and shrinks tumors. However, the study was withdrawn before enrolling any participants, so n…

This study is testing an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check safety and find the right dose. About 195 adults with various solid tumors wil…

This early-stage study tests an experimental pill, ATV-1601, for people with advanced solid tumors or certain breast cancers that have a specific AKT1 gene mutation. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 134 ad…

This early-stage study tests an experimental drug called IMP321, which aims to boost the immune system against cancer. It is given alongside standard treatments like chemotherapy or immunotherapy to people with advanced solid tumors that have spread. The main goal is to see if th…

This early-phase study tests whether infusions of white blood cells (mainly granulocytes) from healthy, unrelated donors can help shrink solid tumors in 29 people with advanced cancer who have no other treatment options. Participants receive daily infusions from different donors …

This study tests the safety and effectiveness of pembrolizumab in preventing cancer from coming back in people who have had a solid tumor removed but still have tumor DNA in their blood. Participants receive the drug or a placebo for up to 12 months. The goal is to see if the dru…

This early-stage study tests a new treatment for children and young adults with high-risk solid tumors that have not responded to standard therapy or have come back. The treatment uses specially grown immune cells that can recognize and attack multiple targets on cancer cells. Th…

This early-stage study tests a flavored, drinkable version of the chemotherapy drug irinotecan (VAL-413) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest and most effective d…

This early-phase study tests a new drug called runimotamab, given alone or with trastuzumab, in people with advanced HER2-expressing cancers. The main goal is to check safety and how the drug moves through the body. About 123 adults with solid tumors that have spread or cannot be…

This study offers continued treatment with avelumab, an immunotherapy drug, to people with advanced cancers (like lung, ovarian, or bladder cancer) who are already benefiting from it in earlier Pfizer studies. The goal is to keep providing the drug and monitor safety and survival…

This early-phase study tests a new experimental drug (BI 3923948) in 60 adults with advanced solid tumors that have spread and are not responding to standard treatments. The drug is injected directly into tumors, either alone or combined with an immune-boosting antibody (checkpoi…

This early-stage study tests a new drug called MK-2870, alone or with other cancer treatments, in 30 Japanese adults with advanced solid tumors or a type of lung cancer. The main goal is to check safety and find the right dose. This is not a cure, but aims to control the disease.

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This early-stage study tests an experimental drug called INCB186748 in people with advanced or spreading solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety and find the right dose. About 30 adults whose cancer has not …

This early-stage trial tests a new treatment called GK01 cell injection combined with an immunotherapy drug (PD-1 antibody) in 15 adults with advanced solid tumors that have spread or come back. The main goal is to check safety and how the body handles the treatment, with early s…

This study tests a new antibody drug, acasunlimab, in people with advanced solid tumors that have stopped responding to standard treatments. The first part checks safety and finds the best dose, while the second part sees how well it works alone or with other cancer drugs. About …

This study tests an experimental drug called M9140 in people with advanced solid tumors (stomach, lung, or pancreatic cancer) that have a specific protein called CEACAM5. The drug is designed to deliver a powerful chemotherapy directly to cancer cells, aiming to shrink tumors whi…

This study tests an experimental drug, BI 1831169, in adults with advanced solid tumors that cannot be removed by surgery or have spread. The drug is given alone or with a standard immunotherapy (anti-PD-1 antibody) to find the safest dose and see if it can shrink tumors. About 1…

This early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This study tests an experimental drug called entrectinib in children and teens with advanced solid tumors or brain tumors that have come back or not responded to other treatments. The goal is to find the best dose and see if the drug shrinks tumors, especially in those with speci…

This study is for people with advanced solid tumors that have spread or cannot be removed by surgery. Researchers use a genetic test to find specific changes in the tumor and then give a treatment designed to target those changes. The goal is to see if these personalized treatmen…

This study tests an experimental drug called ASTX660 in people with advanced solid tumors or lymphomas who have run out of standard treatment options. The goal is to find a safe dose and see if the drug can shrink tumors or control the disease. About 253 adults will take part in …

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study looked at whether ginseng can help control fatigue and related symptoms like depression and anxiety in 165 adults with advanced solid tumors. Participants rated their fatigue levels before and after taking ginseng or a placebo for 29 days. The goal was to see if ginsen…

This study tested whether dexamethasone, a steroid, can reduce common symptoms like fatigue, pain, nausea, and poor appetite in people with advanced cancer. About 132 adults with at least three moderate-to-severe symptoms took part. Researchers measured changes in fatigue and oth…

This study collects leftover tissue and blood samples from 1,200 adults with known or suspected cancer during their standard surgeries or biopsies. Researchers will compare cancerous and normal tissues to find differences that could lead to new cancer treatments. No extra procedu…

This study collects blood samples from people who have unexpected or severe side effects from drugs they are taking in other NIH trials. The goal is to measure drug levels in the blood to better understand why side effects happen. About 100 participants aged 2 and older will take…

This study aims to understand why some solid tumors stop responding to targeted therapies by analyzing their genetic profiles. Researchers will collect blood, saliva, and tumor samples from 2500 people with various cancers, including colorectal, breast, lung, and rare tumors. Som…

This study follows up to 500 children who received gene therapy for cancer through the National Cancer Institute. Researchers will monitor them for 15 years to detect any delayed side effects from the treatment. Participants will have regular check-ups and blood tests to track th…

This study looks at how safe and doable different levels of aerobic exercise are for people about to have surgery for solid tumors like breast, endometrial, or prostate cancer. About 60 participants will exercise at home while using apps and devices to track their activity. The g…

This early-phase study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib. About 64 adults with advanced solid tumors that no longer respond to standard treatments will take both drugs. The goal is to gather safety and…

This study looks at two different pill versions of the cancer drug AZD2281 in people with advanced solid tumors that have not responded to standard treatments. The main goal is to compare how well the body absorbs each version. About 197 participants will take both forms at diffe…